300347 泰格医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.2344.2661.9439.97210.643
总资产报酬率 ROA (%)0.1723.1141.3897.0897.840
投入资产回报率 ROIC (%)0.2043.6611.6278.2779.110

边际利润分析
销售毛利率 (%)26.63927.41533.95438.57739.637
营业利润率 (%)22.52814.77310.06233.68036.446
息税前利润/营业总收入 (%)23.76416.14410.63932.23534.257
净利润/营业总收入 (%)18.32311.7826.78229.11632.062

收益指标分析
经营活动净收益/利润总额(%)38.65151.849149.45573.53474.609
价值变动净收益/利润总额(%)57.07647.455-50.42427.76524.701
营业外收支净额/利润总额(%)0.026-0.6180.0060.0640.115

偿债能力分析
流动比率 (X)2.3022.1791.7202.7412.978
速动比率 (X)2.2832.1641.7122.7352.972
资产负债率 (%)14.70714.46616.06717.61117.363
带息债务/全部投入资本 (%)10.8609.93113.09414.35313.711
股东权益/带息债务 (%)798.807879.094644.373578.707604.915
股东权益/负债合计 (%)493.828510.912448.724402.258410.935
利息保障倍数 (X)19.31911.04218.455-21.973-15.350

营运能力分析
应收账款周转天数 (天)69.09372.85371.43355.78646.665
存货周转天数 (天)3.3182.6662.2851.8101.191